CSIMarket Company Name, Ticker, Suppliers, else..
 
Yield10 Bioscience inc   (YTEN)
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 1
 Employees 28
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Business Description


Yield10 Bioscience Inc. is a biotechnology company that focuses on developing novel crop traits to enhance food and feed production. Their primary goal is to improve crop yield, stress tolerance, and nutritional value using advanced biotechnology tools and techniques. Yield10 Bioscience aims to address challenges in global food security and environmental sustainability by creating more productive and sustainable agricultural practices. They work on multiple crops such as canola, soybeans, and corn, and are committed to delivering innovative solutions to meet the increasing demand for food and feed worldwide.


   Company Address: 19 Presidential Way Woburn 1801 MA
   Company Phone Number: 583-1700   Stock Exchange / Ticker: YTEN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Partnership

Nufarm Strikes Multi-Million Dollar Deal with Yield10 Bioscience for Omega-3 Assets and Potential Acquisition

Published Wed, Jul 17 2024 12:31 PM UTC

In a groundbreaking move within the agricultural and bioscience industry, Nufarm, a leading global agricultural solutions provider, has secured a lucrative commercial license from Yield10 Bioscience. The license grants Nufarm exclusive rights for the production of oil in camelina, a potent source of omega-3 assets. Additionally, both companies have entered into a Memorandum ...
Licensing Agreement

Unveiling the Future of Omega-3 Yield10 Bioscience and Rothamsted Research Pioneer Sustainable Production ...

Published Mon, Jun 17 2024 12:33 PM UTC

In an era marked by a burgeoning need for sustainable and scalable food sources, a recent collaboration between Yield10 Bioscience and Rothamsted Research signals a turning point in the production of omega-3 oils. These long-chain fatty acids, integral to human health, aquafeed, and pet nutrition, could soon see a transformative shift thanks to advances in genetic engineerin...
Shares

Yield10 Bioscience Implements a Reverse Stock Split to Boost Shareholder Value

Published Wed, May 1 2024 12:30 PM UTC



WOBURN, Mass., May 01, 2024 - Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, announced today its plan to carry out a 1-for-24 reverse stock split of its common stock. The reverse stock split received stockholder approval during a special stockholder meeting held on April 26, 2024. This strategic move aims to enhance shareholder value an...
Product Service News

Yield10 Bioscience Receives Clearance for Genome-Edited E3902 Camelina in Canada for Biofuel and Omega-3 Oil Industries.

Published Tue, Mar 26 2024 12:29 PM UTC

Yield10 Bioscience Receives Approval for Genome-Edited E3902 Camelina in CanadaWOBURN, Mass. - In a significant development for agricultural bioscience, Yield10 Bioscience, Inc. (Nasdaq:YTEN) announced that the Plant Biosafety Office (PBO) of the Canadian Food Inspection Agency (CFIA) has cleared the company s genome-edited E3902 Camelina sativa (Camelina) for planting in Ca...
Product Service News

USDA Approves Yield10 Biosciences' Omega-3 Camelina Varieties for Commercial Production

Published Thu, Mar 21 2024 12:30 PM UTC

In a major breakthrough, Yield10 Biosciences, a Boston-based agricultural bioscience company, has received a green light from the United States Department of Agriculture s Animal and Plant Health Inspection Service (USDA-APHIS) to cultivate and breed their Omega-3 Camelina varieties in the United States. This approval marks a significant milestone for the company, paving the...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.1
Working Capital Ratio 0.16
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -10.63 $
Revenues (TTM) 1.17 $
Cash Flow (TTM) -
Cash 1.14 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 26,786
Net Income per Employee (TTM) -453,643
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.19

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -711.78 %
Net Margin (MRQ) -719.56 %
Net Cash Flow Margin (MRQ) -130.44 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.